📣 We're excited to announce that we have signed the Memorandum of Understanding with Open@Work, a non-profit umbrella organization in Belgium spearheading inclusivity for the LGBTQIA+ community and its allies across different companies and organizations. 🌈 This signature officially formalizes our membership with Open@Work, paving the way for us to participate in events, collaborate on initiatives and continue building an inclusive work environment in which everyone is valued, respected and free to fully express themselves. At UCB we are firm in our belief that diversity, equity and inclusion are not just about policies; they are integral to our culture. 🤝 This partnership reaffirms our commitment to DE&I - because at UCB, everyone's voice matters.
From HR trainee to leading a global team—meet Evangelo Chatzikalymnios, our Head of Global Compensation. His story highlights the freedom you have to forge your own career path at UCB. Starting as a trainee 12 years ago, he was given the support he needed to embark on a path of continuous development, seizing opportunities and gaining skills to advance his career and achieve his ambitions. If you too are ready to build on your strengths and drive growth for yourself, whilst creating a meaningful impact for people living with severe diseases, join us... Learn more at UCB Careers https://careers.ucb.com/global/en
At UCB, our mission has always been to create value for patients, now and into the future. We are driven by a profound sense of purpose – to push the boundaries of what's possible in order to improve the lives of people living with severe diseases. It's with great pride and excitement that we inaugurate our new state-of-the-art biotechnology plant at our UCB Braine-l'Alleud Campus. This strategic investment is not just a physical structure; it's a manifestation of our unwavering commitment to pioneering innovation and delivering unique outcomes to patients. Over the past 18 months, our innovative spirit has yielded remarkable results: 10 + 2 positive phase 3 readouts and 14 approvals, spanning 6 patient populations across 3 continents. Our rich pipeline boasts 10 potential different medicines, each holding the promise to transform lives. Learn more...
Every year, World Intellectual Property Day is the opportunity to celebrate one of the many contributions IP brings to our lives, and specifically this year, to our sustainable development ambition, and ultimately to a better world, through innovation. This ambition was captured in the 2030 Agenda for Sustainable Development, adopted by all United Nations Member States in 2015. The Sustainable Development Goals (SDGs) are at the heart of this agenda: 17 goals representing our aspirations or a common, peaceful and prosperous future; 17 goals towards which we should all take action. Learn more...
Closing the gap in osteoporosis: It’s make or break for post-fracture care: We can’t escape the facts. Around the world, the treatment gap in osteoporosis continues to be as pervasive as it is affecting; in an international survey last year, the International Osteoporosis Foundation (IOF) revealed that almost one in two women after the age of 50 and over experienced a fracture. Paradoxically, bone health – and the chance to identify and treat the underlying osteoporosis – was neglected during medical check-ups. The ramifications of this missed opportunity are huge. Why does this matter? The impact on daily life for women with osteoporosis should not be underestimated, with fractures marked by excruciating pain, immobilization, and prolonged hospitalization, robbing them of their independence. This can have a significant impact on their well-being, leaving women feeling anxious and isolated. The lack of appropriate intervention at this crucial trigger point of the patient journey places a staggering burden on healthcare systems, with the cost of fractures in the EU anticipated to hit 77 billion EUR by 2050. In the past year, we have made great progress in elevating secondary fracture prevention on government agendas. Learn more...
World Parkinson’s Day: Why the urgency for innovation grows greater every year: As we mark another World Parkinson’s Day, my experience in patient-centered research has taught me one thing: the urgency for innovation in this disease area grows greater every year. The vision of the Parkinson’s Community is to reach the goal of disease modification – to alter the course of Parkinson’s using interventions that target the underlying cause of disease. However, for me, the term ‘disease modification’ can be a bit of a banana skin, likely to trip us up, and raise more questions than it answers. People with Parkinson’s currently rely on symptomatic treatments, interventions that were assessed in late-stage Parkinson’s with established outcome measures, such as the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). In contrast, disease modification will require early intervention in people with early-stage Parkinson’s, who experience a variety of motor and non-motor symptoms that cannot be assessed in a sufficient granular way using existing outcome measures. This, in a field without valid biomarkers and where even the definition of early-stage Parkinson’s disease can be unclear! Our recent collaboration with people with Parkinson’s to co-create patient-reported outcomes (PROs) sought to answer some of these questions. Learn more...
Advocating for Change in the Lives of People with Hidradenitis Suppurativa At UCB, we are committed to improving the lives of people living with hidradenitis suppurativa (HS), a chronic, painful, inflammatory skin condition that can have a significant and detrimental impact on patients’ lives. Today, there are several barriers for people living with HS, which can impede their ability to live life to the fullest potential. These include insufficient awareness of HS and delays in diagnosis. These factors can impact the timely and appropriate care that people with HS receive. Additionally, the stigma associated with the disease can negatively affect mental wellbeing and interpersonal relationships.1 Addressing these barriers is a crucial step towards improving lives. Learn more...
The 13th Conference of the European Hidradenitis Suppurativa Foundation is taking place this week in Lyon, France (Feb 7-9). At UCB, we have a longstanding commitment to developing and delivering science that will make a difference in the lives of people with immuno-dermatological conditions and we’re proud to be a platinum sponsor of this Conference, exclusively dedicated to hidradenitis suppurativa (HS).
Denelle Waynick Johnson, Executive Vice President and General Counsel at UCB reflects on intersectionality and how the different aspects of her own identity are interconnected and linked to her personal and professional path. Read more...
At UCB we are ‘driven by science’, it’s a key aspect of our culture. Being driven by science signifies a commitment to making decisions and taking actions based on evidence, research, and empirical data. It means adopting novel technologies, exploring new modalities, and embracing the quest for knowledge, understanding, and truth that is at the heart of scientific endeavor. Read more...
